DigiTx Partners

Embr Labs Awarded Six Patents for AI-Driven Digital Therapeutics! This milestone is a testament to the innovation and dedication of our team. My co-founder, Matthew Smith, has been leading Embr's Intellectual Property development from day one. When we drafted our first provisional patent back in October 2013, I didn’t realize how much of a marathon (or maybe an ultra-marathon!) the patent process would be. But Matt’s long-term vision, persistence, and unwavering commitment have been instrumental in advancing and protecting Embr’s groundbreaking technology. These six patents reflect our mission to push the boundaries of AI-driven thermal wellness and deliver real impact for our customers. Here’s to more innovation ahead! Read more about this exciting milestone here: https://lnkd.in/gMaB6XuB

We are pleased to announce that we have listed our new #DigitalHealth solution for the management of #HeartFailure with the U.S. Food and Drug Administration (FDA).? Heart failure is a global health issue affecting more than 64 million people worldwide. In the U.S., the prevalence of heart failure is 6.9 million (2020 estimate) and is expected to increase by 24% to nearly 8.5 million by 2030 due to the aging and growth of the U.S. population. This milestone represents an important step forward in helping patients impacted by heart failure take a more active role in managing their health. We are proud to offer a non-invasive digital health option that enables at-home disease monitoring and physician intervention when necessary.? ? Read more here:? https://lnkd.in/gX7zgZVT

Eko Health's AI ?????????????? ?????? ?????????????????? ???? ?????????? ?????????????? ???? ???????????????? ?????????? in a recent randomized controlled clinical trial published in Nature Medicine. Led by Dr. Demilade Adedinsewo at Mayo Clinic, the trial evaluated the performance of Eko’s recently FDA-cleared Low EF AI technology in detecting ejection fraction (EF) at several thresholds, a key metric of heart pump function typically captured using cardiac ultrasound. Involving over 1,200 participants, the study demonstrated that Eko’s Low EF AI technology enabled healthcare professionals to detect PPCM at twice the rate of traditional obstetric care. “This study represents a significant step forward in using AI to address critical healthcare challenges, particularly in underserved regions where maternal health outcomes are most at risk,” said Connor Landgraf, CEO and co-founder of Eko Health. “Our mission at Eko has always been to bridge the gap in cardiovascular care access through innovative technology. The results of this trial reinforce our commitment to providing accessible, life-saving tools to healthcare providers around the world, enabling them to detect heart disease earlier and improve patient outcomes.” Learn more: https://lnkd.in/gJB7NSxZ

ciba health! Amazing team that's scaling and helping patients. Excited to support them! https://lnkd.in/gUUapyFF